LAVA Therapeutics N.V. announced Ed Smith, chief financial officer has resigned to pursue other interests, effective as of May 17, 2022. He may serve in a consulting capacity to support the Company's transition. The Company has commenced a search for Mr. Smith's permanent replacement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.34 USD | -2.50% |
|
+2.18% | +48.10% |
05-21 | LAVA Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
03-20 | LAVA Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+48.10% | 61.52M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- LVTX Stock
- News LAVA Therapeutics N.V.
- LAVA Therapeutics N.V. Announces the Resignation of Ed Smith as Chief Financial Officer